The disclosure provides 3D bioprinted test beds and methods of making the 3D bioprinted teste beds, methods of using the 3D bioprinted test beds for testing and/or comparatively testing two or more test compounds on cell growth and/or behavior, as well as biocompatible methacrylated hyaluronic acid-based bioinks for printing the 3D test beds and/or other articles. The 3D test beds and bioinks include a hydrogel material/precursor and can include extracellular matrix components.

The present disclosure provides a method for identifying a nucleic acid, which may comprise incubating a cell that has been or is suspected of having been transfected or transduced with an exogenous ribonucleic acid (RNA) molecule or an exogenous deoxyribonucleic (DNA) molecule. Next, a morphological change of the cell may be identified. Next, contents of the cell may be processed to identify a nucleic acid sequence or a peptide, polypeptide, or protein or a sequence of the peptide, polypeptide, or protein. Next, the nucleic acid sequence or the peptide, polypeptide, or protein or the sequence of the peptide, polypeptide, or protein may be analyzed to determine an exogenous sequence of the exogenous RNA molecule or the exogenous DNA molecule. Next, the exogenous sequence of the exogenous RNA molecule or the exogenous DNA molecule may be identified as effecting the morphological change of the cell. The exogenous RNA molecule or the exogenous DNA molecule may encode genes or peptides, polypeptides, or proteins that inhibit, activate, or modulate a biochemical pathway within the cell, thereby causing the morphological change of the cell.

Embodiments herein described provide methods for determining phenotypic parameters of cell populations and expressing them in terms of tensors that can be compared with one another. Embodiments provide methods for determining phenotypic parameters of cell populations in response to an agent. Embodiments provide methods for comparing effects of an agent on phenotypic parameters to effects of reference standards whose in vivo effects are known. Embodiments provide methods for predicting the effect of an agent by the comparison with the known effects of reference standards. Embodiments provide methods for classifying agents by their effects on phenotypic parameters. Embodiments provide software and computer systems for calculating multiparametric tensors, compressing their complexity and comparing them after compression.

The invention provides methods of decreasing immune response by inhibiting iron-dependent cellular disassembly. The decrease in immune response may be used, for example, for treatment of a disorder associated with iron-dependent cellular disassembly, including an autoimmune disorder, allergy, or an inflammatory disorder. The invention also provides screening assays for identification of compounds that inhibit iron-dependent cellular disassembly and are also immunoinhibitory agents.

This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

This invention relates to methods of identifying, synthesizing, optimizing and profiling compounds that are inhibitors or activators of proteins, both naturally occurring endogenous proteins as well as certain variant forms of endogenous proteins, and novel methods of identifying such variants. The method accelerates the identification and development of compounds as potential therapeutically effective drugs by simplifying the pharmaceutical discovery and creation process through improvements in hit identification, lead optimization, biological profiling, and rapid elimination of toxic compounds. Implementation results in overall cost reductions in the drug discovery process resulting from the corresponding increases in efficiency.

The invention relates to methodologies of obtaining a controlled exposure of an aerosol to a model material. The invention also provides an exposure cap and a system for studying or predicting the interaction between a model material, e.g. a cell, and an aerosolized agent. The controlled exposure of the aerosol to the model material, makes is possible to accurately calculate the mass-balance of the aerosol exposure.

[Object] To evaluate the function related to absorption or release of a biological sample in more detail. [Solution] According to the present technology, an information processing device includes: a detection unit configured to detect at least one region of interest in at least one captured image among a plurality of captured images of a biological sample having different imaging times; a feature amount calculation unit configured to calculate a feature amount related to a change in the at least one region of interest in the plurality of captured images; and an evaluation value calculation unit configured to calculate an evaluation value for a function related to absorption or release of the biological sample on a basis of the feature amount.

The invention relates to an assay for diagnosing a disease or affliction that affects fluid uptake or secretion or for studying the effectiveness of one or more drugs for treating the disease or affliction, wherein the assay comprises measuring swelling of one or more organoids.

The present invention relates a method for chemical testing, comprising culturing cells in a first plant-derived nanofibrillar cellulose (NFC)hydrogel to obtain in vivo like cells; exposing the in vivo like cells to a test chemical; optionally within another plant-derived NFC hydrogel; incubating the exposed in vivo like cells; detecting during or after incubating, the impact of the test chemical on the in vivo like cells by at least one detection; and removing the plant-derived NFC hydrogel at least once at any stage after obtaining the in vivo like cells and before at least one detection used for detecting the impact of the test chemical on the in vivo like cells. The invention further relates to the use of plant-derived NFC hydrogel in a method for chemical testing, the use of in vivo like cells obtained by culturing cells in plant-derived NFC hydrogel for chemical testing and to a kit for chemical testing comprising plant-derived NFC hydrogel, instructions and a cell or test chemical library.